Clinical Trial Update: Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding Due to Trauma [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating recombinant Factor VIIa for severe bleeding due to trauma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acquired Bleeding Disorders
• Traumatic Injuries

Drugs mentioned

• NovoSeven (recombinant coagulation factor VIIa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Acquired Bleeding Disorder, Trauma | Phase 3 | Status: WITHDRAWN